GleamWall
中文EN

VSBC VITASPRING BIOMEDICAL CO. LTD.

Services-Commercial Physical & Biological Research · OTC · SEC CIK 1697884 · Fiscal year ends 01/31

Financial factors as of 2026-07-31 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY14.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-2,861.9%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets31,554.8%
Debt / equity—
Current ratio0.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.02x
Accruals ratio-2,928.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-01-31FY20252025-01-31
Income statement
Revenue$0$0
Cost of revenue$0$0
Gross profit$0$0
SG&A expense$385,411$679,914
Operating income-$385,411-$679,914
Pretax income-$385,411-$679,914
Income tax$29,957$95,008
Net income-$415,368-$774,922
EBITDA-$375,454-$669,957
EPS (diluted)0.000.00
Weighted avg. shares (diluted)207.03M207.03M
Balance sheet
Cash & equivalents$2,084$272
Receivables—$0
Current assets$10,527$272
PP&E, net$4,149$14,106
Total assets$14,676$14,378
Current liabilities$4.45M$4.03M
Total liabilities$4.45M$4.03M
Shareholders' equity-$4.43M-$4.02M
Shares outstanding207.03M207.03M
Cash flow statement
Operating cash flow-$2,688-$14,675
Financing cash flow$4,500$14,934
Depreciation & amortization$9,957$9,957
Stock-based compensation$0$109,911

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.